Evidence map›Paper›PMID 25066141›Full record

ArticlePsychological medicine2014

The effects of co-morbidity in defining major depression subtypes associated with long-term course and severity.

K J Wardenaar, H M van Loo, T Cai, M Fava, M J Gruber, J Li, P de Jonge, A A Nierenberg, M V Petukhova, S Rose and 21 more

Abstract read
In one paragraph

Article in Psychological medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 11 institutions in 7 countries.

K J WardenaarDepartment of Psychiatry,University of Groningen, University Medical Center Groningen,The Netherlands.
H M van LooDepartment of Psychiatry,University of Groningen, University Medical Center Groningen,The Netherlands.
T CaiDepartment of Biostatistics,Harvard School of Public Health,Boston, MA,USA.
M FavaDepartment of Psychiatry,MGH Clinical Trials Network and Institute,Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA,USA.
M J GruberDepartment of Health Care Policy,Harvard Medical School,Boston, MA,USA.
J LiDepartment of Biostatistics,Harvard School of Public Health,Boston, MA,USA.
P de JongeDepartment of Psychiatry,University of Groningen, University Medical Center Groningen,The Netherlands.
A A NierenbergDepression Clinical and Research Program and the Bipolar Clinic and Research Program,Massachusetts General Hospital and Harvard Medical School,Boston, MA,USA.
M V PetukhovaDepartment of Health Care Policy,Harvard Medical School,Boston, MA,USA.
S RoseDepartment of Health Care Policy,Harvard Medical School,Boston, MA,USA.
N A SampsonDepartment of Health Care Policy,Harvard Medical School,Boston, MA,USA.
R A SchoeversDepartment of Psychiatry,University of Groningen, University Medical Center Groningen,The Netherlands.
M A WilcoxJohnson & Johnson Pharmaceutical Research and Development,Titusville, NJ,USA.
J AlonsoIMIM-Hospital del Mar Research Institute, Parc de Salut Mar,Pompeu Fabra University (UPF), andCIBER en Epidemiología y Salud Pública (CIBERESP), Barcelona,Spain.
E J BrometDepartment of Psychiatry and Behavioral Science, Stony Brook School of Medicine,State University of New York at Stony Brook,Stony Brook, NY,USA.
B BuntingPsychology Research Institute,University of Ulster,Londonderry,UK.
S E FlorescuNational School of Public Health,Management and Professional Development, Bucharest,Romania.
A FukaoDepartment of Public Health,Yamagata University School of Medicine,Japan.
O GurejeUniversity College Hospital,Ibadan,Nigeria.
C HuShenzhen Institute of Mental Health and Shenzhen Kangning Hospital,Guangdong Province,People's Republic of China.
Y Q HuangInstitute of Mental Health, Peking University,Beijing,People's Republic of China.
A N KaramDepartment of Psychiatry and Clinical Psychology,St George Hospital University Medical Center,Department of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University Medical School, andInstitute for Development Research Advocacy and Applied Care (IDRAAC), Beirut,Lebanon.
D LevinsonResearch and Planning,Mental Health Services,Ministry of Health, Jerusalem,Israel.
M E Medina MoraNational Institute of Psychiatry,Calzada Mexico Xochimilco, Mexico City,Mexico.
J Posada-VillaUniversidad Colegio Mayor de Cundinamarca,Bogota,Colombia.
K M ScottDepartment of Psychological Medicine,University of Otago,Dunedin,New Zealand.
N I TaibMental Health Center-Duhok,Kurdistan Region,Iraq.
M C VianaDepartment of Social Medicine,Federal University of Espirito Santo,Vitoria,Brazil.
M XavierDepartment of Mental Health,Universidade Nova de Lisboa,Lisbon,Portugal.
Z ZarkovNational Center of Public Health and Analyses,Department of Mental Health, Sofia,Bulgaria.
R C KesslerDepartment of Health Care Policy,Harvard Medical School,Boston, MA,USA.
Harvard University · USUniversity Medical Center Groningen · NLIsrael Ministry of Health · ILJohnson & Johnson (United States) · USSt George's Hospital · GBStony Brook University · USUniversidade Federal do Espírito Santo · BRUniversity College Hospital, Ibadan · NGUniversity of Groningen · NLUniversity of Ulster · GBYamagata University · JP

Funding

EPIDEMIOLOGY-- NATIONAL COMORBIDITY SURVEY REPLICATIONU01MH060220 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KESSLER, RONALD C · 1999 to 2010
$18.7M
Risk Factors for Psychopathology in the WHO WMH SurveysR01MH070884 · NIMH · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KESSLER, RONALD C · 2005 to 2009
$6.0M
Social Role Disability and Mental-Physical Co-MorbidityR01MH069864 · NIMH · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI VON KORFF, MICHAEL R · 2004 to 2007
$2.2M
COMORBID MENTAL DISORDERS IN PERIODS OF SOCIAL DISRUPTIOR01MH061905 · NIMH · STATE UNIVERSITY NEW YORK STONY BROOK · PI BROMET, EVELYN J · 2000 to 2004
$1.7M
CROSS-NATIONAL STUDIES OF DRUG INVOLVEMENT: WMH2000R01DA016558 · NIDA · MICHIGAN STATE UNIVERSITY · PI ANTHONY, JAMES CHRISTOPHER · 2003 to 2008
$1.7M
Drug Dependence Epidemiology and EnviromicsK05DA015799 · NIDA · MICHIGAN STATE UNIVERSITY · PI ANTHONY, JAMES CHRISTOPHER · 2003 to 2015
$1.4M
World Mental Health Consortium Annual Meeting 2003-07R13MH066849 · NIMH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HEERINGA, STEVEN G · 2003 to 2007
$735k
Lebanon-Epidemiology: The NCS Replication StudyR03TW006481 · FIC · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KESSLER, RONALD C · 2004 to 2006
$142k
FIC NIH HHS R03 TW006481FIC NIH HHS R03-TW006481FIC NIH HHS R03 TW006481-01Medical Research Council MR/K023241/1NIDA NIH HHS K05 DA015799NIDA NIH HHS R01 DA016558NIMH NIH HHS R01 MH061905NIMH NIH HHS R01 MH069864NIMH NIH HHS R01-MH069864NIMH NIH HHS R01 MH070884NIMH NIH HHS R01-MH61905NIMH NIH HHS R13 MH066849NIMH NIH HHS R13-MH066849NIMH NIH HHS U01 MH060220NIMH NIH HHS U01-MH60220
6 · The paper itself

Abstract

backgroundAlthough variation in the long-term course of major depressive disorder (MDD) is not strongly predicted by existing symptom subtype distinctions, recent research suggests that prediction can be improved by using machine learning methods. However, it is not known whether these distinctions can be refined by added information about co-morbid conditions. The current report presents results on this question.

methodData came from 8261 respondents with lifetime DSM-IV MDD in the World Health Organization (WHO) World Mental Health (WMH) Surveys. Outcomes included four retrospectively reported measures of persistence/severity of course (years in episode; years in chronic episodes; hospitalization for MDD; disability due to MDD). Machine learning methods (regression tree analysis; lasso, ridge and elastic net penalized regression) followed by k-means cluster analysis were used to augment previously detected subtypes with information about prior co-morbidity to predict these outcomes.

resultsPredicted values were strongly correlated across outcomes. Cluster analysis of predicted values found three clusters with consistently high, intermediate or low values. The high-risk cluster (32.4% of cases) accounted for 56.6-72.9% of high persistence, high chronicity, hospitalization and disability. This high-risk cluster had both higher sensitivity and likelihood ratio positive (LR+; relative proportions of cases in the high-risk cluster versus other clusters having the adverse outcomes) than in a parallel analysis that excluded measures of co-morbidity as predictors.

conclusionsAlthough the results using the retrospective data reported here suggest that useful MDD subtyping distinctions can be made with machine learning and clustering across multiple indicators of illness persistence/severity, replication with prospective data is needed to confirm this preliminary conclusion.

Indexed as

ComorbidityDisease ProgressionSeverity of Illness IndexAdolescentAdultAgedAged, 80 and overArtificial IntelligenceCluster AnalysisFemaleGlobal HealthHumansMajor Depressive DisorderMaleMiddle AgedRetrospective Studies

Identifiers

PMID25066141
PMCPMC4180779
OpenAlexW2136681395

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.